Harvard Apparatus Regenerative Technology (HRGN) Q1 2026 earnings summary

Executive summary

• Clinical-stage biotech focused on regenerative medicine for GI disorders and consumer health products, with two operating segments: Regenerative Biotech and Consumer Health Products.

• First esophageal implant product in Phase 1 clinical trial; patient recruitment delays due to stringent criteria and logistics.

• Consumer Health Products segment sells dietary supplements in Asia, showing strong revenue growth.

Financial highlights

• Product revenue rose 402% year-over-year to $226,000 for Q1 2026, driven by expanded distribution and new product launches in Consumer Health.

• Net loss for Q1 2026 was $1.6 million, a 3% improvement from Q1 2025.

• Operating expenses totaled $1.83 million, up 7% year-over-year, with R&D down 6% and G&A down 2%.

• Cash and cash equivalents were $419,000 as of March 31, 2026, down from $1.35 million at year-end 2025.

• Accumulated deficit reached $108.2 million as of March 31, 2026.

Outlook and guidance

• Management expects continued operating losses and negative cash flows for 2026 and beyond.

• Current cash and recent $0.5 million bridge loan expected to fund operations into Q2 2026; additional capital required to continue operations.